Evaluation of Two Daily Disposable Contact Lenses for Wearers With Astigmatism
Study Details
Study Description
Brief Summary
The purpose of this trial is to compare the performance of two contact lenses for contact lens wearers with astigmatism.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Other: Nelfilcon A invest'l / nelfilconA comm'l Nelfilcon A investigational toric contact lenses worn first, with nelfilcon A commercial toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week. |
Device: Nelfilcon A investigational contact lens
Investigational, soft contact lens for astigmatism worn on a daily disposable basis.
Device: Nelfilcon A commercial contact lens
Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.
Other Names:
|
Other: Nelfilcon A comm'l / nelfilconA invest'l Nelfilcon A commercial toric contact lenses worn first, with nelfilcon A investigational toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week. |
Device: Nelfilcon A investigational contact lens
Investigational, soft contact lens for astigmatism worn on a daily disposable basis.
Device: Nelfilcon A commercial contact lens
Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Quality of Vision (Crisp and Clear) [1 week of wear]
Quality of vision (crisp and clear), as interpreted and reported by the participant by eye on a questionnaire as a single, retrospective evaluation of one week's wear time. Quality of vision was assessed on a 10-point scale, with 1 being poor and 10 being excellent.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Currently wearing soft contact lenses with astigmatism correction
-
Other protocol inclusion criteria may apply
Exclusion Criteria:
-
Eye injury or surgery within twelve weeks prior to enrollment
-
Currently enrolled in an ophthalmic clinical trial
-
Strabismus
-
Any use of medications for which contact lens wear could be contraindicated as determined by the investigator
-
Other protocol exclusion criteria may apply
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- CIBA VISION
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- P-415-C-001 sub 2
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail | This reporting group includes all enrolled and dispensed participants. One participant was enrolled but not dispensed due to unacceptable fit. This participant is included in the Actual Enrollment calculation, but not Participant Flow or Baseline Characteristics calculations. |
Arm/Group Title | Nelfilcon A Invest'l / nelfilconA Comm'l | Nelfilcon A Comm'l / nelfilconA Invest'l |
---|---|---|
Arm/Group Description | Nelfilcon A investigational toric contact lenses worn first, with nelfilcon A commercial toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week. | Nelfilcon A commercial toric contact lenses worn first, with nelfilcon A investigational toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week. |
Period Title: Period 1, One Week of Wear | ||
STARTED | 46 | 48 |
COMPLETED | 46 | 48 |
NOT COMPLETED | 0 | 0 |
Period Title: Period 1, One Week of Wear | ||
STARTED | 45 | 48 |
COMPLETED | 45 | 48 |
NOT COMPLETED | 0 | 0 |
Baseline Characteristics
Arm/Group Title | Overall |
---|---|
Arm/Group Description | This reporting group includes all enrolled and dispensed subjects. |
Overall Participants | 94 |
Age (years) [Mean (Standard Deviation) ] | |
Mean (Standard Deviation) [years] |
35.8
(12.2)
|
Sex: Female, Male (Count of Participants) | |
Female |
56
59.6%
|
Male |
38
40.4%
|
Outcome Measures
Title | Quality of Vision (Crisp and Clear) |
---|---|
Description | Quality of vision (crisp and clear), as interpreted and reported by the participant by eye on a questionnaire as a single, retrospective evaluation of one week's wear time. Quality of vision was assessed on a 10-point scale, with 1 being poor and 10 being excellent. |
Time Frame | 1 week of wear |
Outcome Measure Data
Analysis Population Description |
---|
Analysis conducted per protocol, with exclusions due to reasons such as: major protocol deviations as determined by masked review; discontinuations; and/or missing responses. |
Arm/Group Title | Nelfilcon A Investigational | Nelfilcon A Commercial |
---|---|---|
Arm/Group Description | Investigational, soft contact lenses for astigmatism worn bilaterally on a daily disposable basis for one week. | Commercially marketed, soft contact lenses for astigmatism worn bilaterally on a daily disposable basis for one week. |
Measure Participants | 92 | 91 |
Measure eyes | 184 | 182 |
Mean (Standard Deviation) [units on a scale] |
8.8
(1.3)
|
8.6
(1.5)
|
Adverse Events
Time Frame | Adverse event data were collected for the duration of the trial: 45 days. | |||
---|---|---|---|---|
Adverse Event Reporting Description | This reporting group includes all enrolled and exposed participants. | |||
Arm/Group Title | Nelfilcon A Investigational | Nelfilcon A Commercial | ||
Arm/Group Description | Investigational, soft contact lenses for astigmatism worn bilaterally on a daily disposable basis for one week. | Commercially marketed, soft contact lenses for astigmatism worn bilaterally on a daily disposable basis for one week. | ||
All Cause Mortality |
||||
Nelfilcon A Investigational | Nelfilcon A Commercial | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
Nelfilcon A Investigational | Nelfilcon A Commercial | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/95 (0%) | 0/93 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
Nelfilcon A Investigational | Nelfilcon A Commercial | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/95 (0%) | 0/93 (0%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.
Results Point of Contact
Name/Title | Joe Rappon, OD, MS, FAAO / Head, Clinical Trial Management |
---|---|
Organization | CIBA VISION |
Phone | 1-678-415-3343 |
joseph.rappon@cibavision.com |
- P-415-C-001 sub 2